NEWS

Viroclinics-DDL Team to Support COVID-19 New Drug Investigations

Preceding weeks have made clear that COVID-19 continues to spread and is paralyzing the world. Times are unprecedented and show us how vulnerable we are and how we depend on each other. As a service organization – highly specialized in virology – we will commit ourselves to realign our resources, equipment and materials to new initiatives to test anti-virals, immune modulators and vaccines in the battle against COVID-19.

Summit Partners Announces Growth Equity Investment in Viroclinics Biosciences

Global growth equity investor Summit Partners today announced a majority investment in Viroclinics Biosciences B.V., a leading specialized contract research organization (CRO) serving the global biopharmaceutical industry. The funding will be used to fuel continued expansion of Viroclinics’ services, capacity and international presence.

Viroclinics Biosciences and DDL Diagnostic Laboratory Join Forces

Viroclinics Biosciences, a leading virology contract research organization, announced today that it has acquired DDL Diagnostic Laboratory, a leading diagnostic solutions provider. The transaction enhances the combined group’s leading global position in anti-viral and vaccine testing and will serve to accelerate their ambitious growth strategy.

Viroclinics Xplore Joins Trade Mission Life Sciences India

October 13th - October 19th, Delhi & Bangalore Viroclinics Xplore continues its cooperation with The Netherlands Enterprise Agency (RVO). Viroclinics experts will join the upcoming trade mission to India from October 13th to October 19th. The health program of the...

Launch Viroclinics Xplore Business Unit

Due to the growing demand of our global business and the drive to deliver innovative diagnostic services, we are proud to announce the launch of our new business unit, Viroclinics Xplore.

Keep up-to-date

Subscribe to our newsletter for the latest insights on early stage, (pre)clinical research, cold chain logistics and assay development services.

↓